Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Acelrx Pharmaceutica (ACRX)

Acelrx Pharmaceutica (ACRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 179,835
  • Shares Outstanding, K 79,573
  • Annual Sales, $ 2,150 K
  • Annual Income, $ -47,150 K
  • 60-Month Beta 2.01
  • Price/Sales 85.45
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.22
  • Number of Estimates 2
  • High Estimate -0.19
  • Low Estimate -0.25
  • Prior Year -0.18
  • Growth Rate Est. (year over year) -22.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.64 +37.80%
on 11/22/19
2.50 -9.60%
on 12/11/19
+0.48 (+26.97%)
since 11/13/19
3-Month
1.64 +37.80%
on 11/22/19
2.80 -19.29%
on 09/17/19
-0.29 (-11.37%)
since 09/13/19
52-Week
1.64 +37.80%
on 11/22/19
4.09 -44.74%
on 03/05/19
-0.61 (-21.25%)
since 12/13/18

Most Recent Stories

More News
Assertio to Divest Shingles Pain Drug to Alvogen for $127.5M

Assertio (ASRT) inks a deal to sell Gralise to Alvogen for a total value of $127.5 million.

ACRX : 2.26 (-2.16%)
IRWD : 12.79 (+1.35%)
ASRT : 1.19 (-3.25%)
JNCE : 9.21 (unch)
AcelRx Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?

AcelRx Pharmaceuticals, Inc. (ACRX) has been struggling lately, but the selling pressure may be coming to an end soon.

ACRX : 2.26 (-2.16%)
AcelRx Pharmaceuticals Announces Publication Analyzing Pooled Dosing and Efficacy Data on Sufentanil Sublingual 30 mcg Tablets

AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today...

ACRX : 2.26 (-2.16%)
AcelRx Pharmaceuticals Enters Oversold Territory

AcelRx Pharmaceuticals has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

ACRX : 2.26 (-2.16%)
AcelRx Pharmaceuticals (ACRX) Reports Q3 Loss, Misses Revenue Estimates

AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 30.43% and -50.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?...

ACRX : 2.26 (-2.16%)
AcelRx Pharmaceuticals Reports Third Quarter 2019 Financial Results

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings,...

ACRX : 2.26 (-2.16%)
AcelRx Pharmaceuticals to Present at Credit Suisse 28th Annual Healthcare Conference

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the use in medically supervised settings, today...

ACRX : 2.26 (-2.16%)
AcelRx to announce third quarter 2019 results and provide an update on the company's business on Wednesday, November 6th, 2019

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release third quarter financial results after market close on Wednesday, November 6, 2019....

ACRX : 2.26 (-2.16%)
Earnings Preview: AcelRx Pharmaceuticals (ACRX) Q3 Earnings Expected to Decline

AcelRx Pharmaceuticals (ACRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ACRX : 2.26 (-2.16%)
AcelRx Pharmaceuticals (ACRX) Moves to Buy: Rationale Behind the Upgrade

AcelRx Pharmaceuticals (ACRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

ACRX : 2.26 (-2.16%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade ACRX with:

Business Summary

AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of pain. The Company product candidates comprises: ARX-01 or the Sufentanil NanoTab PCA System; ARX-02 or the Sufentanil NanoTab BTP Management System; and...

See More

Key Turning Points

2nd Resistance Point 2.44
1st Resistance Point 2.35
Last Price 2.26
1st Support Level 2.21
2nd Support Level 2.16

See More

52-Week High 4.09
Fibonacci 61.8% 3.15
Fibonacci 50% 2.87
Fibonacci 38.2% 2.58
Last Price 2.26
52-Week Low 1.64

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar